Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
J NUCL MED
1743 - 1745.
Iodine-131-metaiodobenzylguanidine (MIBG) is highly concentrated by >60% of carcinoid metastases and thus provides a therapeutic oppportunity. Methods: A symptomatic patient with carcinoid liver metastases, unresponsive to chemotherapy combined with interferon-alpha, was subsequently treated with I-131-MIBG. Results: Radionuclide therapy, which was without significant side effects, resulted in symptomatic improvement and reduced urinary 5-hydroxyindoleacetic acid levels. No new metastases were observed for 15 mo after I-131-MIBG therapy. Gross cystic change occurred in existing liver metastases, presumably as a result of ischemic necrosis. Surgical deroofing and aspiration of cysts led to regeneration of normal liver tissue. Conclusion: Iodine-131-MIBG therapy can provide prolonged symptomatic relief and improved quality of life in patients with metastatic carcinoid disease unresponsive to other therapies. The antitumor effect of I-131-MIBG was accompanied by few side effects, suggesting that this therapy should be considered in symptomatic patients with an early stage of disease.
|Title:||Iodine-131-MIBG therapy of a patient with carcinoid liver metastases|
|Keywords:||iodine-131 metaiodobenzylguanidine, liver carcinoid, pseudocyst, TUMORS, METAIODOBENZYLGUANIDINE|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > UCL Medical School
Archive Staff Only